GPR68 and endothelial dysfunction: In this context, the GPR68 specific small molecule inhibitor OGM-8345 described in this study holds promise to be developed into a plausible drug candidate for therapeutic treatment of lung inflammatory syndromes associated with endothelial dysfunction owing to its pronounced EC barrier protective and anti-inflammatory properties.